Last Updated on September 9, 2021 by The Health Master
India, Hyderabad: Hetero announced today that the Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India.
This authorization will enable the medical practitioners to use the generic drug Tocilizumab for the treatment of C-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This demonstrates our technical capabilities and commitment to bringing important therapeutics relevant to C-19 care.
This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the Government to ensure equitable distribution.”
Hetero’s biologics arm ‘Hetero Biopharma’ will be manufacturing the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad, India.
Hetero’s Tocilizumab 400mg/20ml is the biosimilar version of Roche’s Actemra/RoActemra ®, and will be available from September end.